HER2 has been considered a therapeutic target because HER2 gene alterations induce a malignant phenotype, it is overexpressed in 15–18% of breast cancer, and it is associated with a poor prognosis for these patients [2]. This evidence concerns the gene ERBB2 and breast carcinoma.